Skip to Content
Upcoming Webinar

Cost Comparison of Osimertinib + Chemo vs Amivantamab + Lazertinib in First-Line EGFR-Mutated NSCLC

Date: September 17, 2025 | 2:00 PM
When: Wednesday, September 17 | 2 p.m. EST

The treatment landscape for EGFR-mutated NSCLC is shifting, with new regimens reshaping first-line care. Beyond clinical outcomes, cost considerations play a critical role in treatment decisions for both patients and payers.

This webinar takes a closer look at the economic impact of osimertinib + chemotherapy compared with amivantamab + lazertinib in patients with locally advanced or metastatic EGFRm NSCLC.

In this session, you will:

  • A clear view of the 1L EGFRm NSCLC treatment landscape
  • Insights into cost-of-care drivers: treatment acquisition, administration, healthcare resource use, and adverse event management
  • Patient- and payer-level cost comparisons between FLAURA2 and MARIPOSA

Speakers:
Ultán McGlone, PharmD | University of Pittsburgh Medical Center
Jorge J. Nieva MD | Keck School of Medicine of USC & USC/Norris Cancer Center

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.